About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiology
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
G
State of the Art and Next Questions: Aggressive B-Cell Lymphomas
By
SOHO Highlights: State of the Art and Next Questions
FEATURING
Grzegorz Nowakowski
By
SOHO Highlights: State of the Art and Next Questions
FEATURING
Grzegorz Nowakowski
0 views
March 29, 2024
Comments
0
Login to view comments.
Click here to Login
Featured Video
16:51
Incyte
Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk
Feat.
C. Harrison
Featured Video
24:35
Indy Hematology Review
Current Approaches in the Treatment of Myeloproliferative Neoplasms
Feat.
A. Tefferi
Recommended
AUTOPLAY
ON
Related
Newest
21:05
Louisville Hematology Highlights
Why Are Our Hematopoietic Stem Cells in the Bone Marrow?
Feat.
R. Gale
16:57
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Summary: "Lymphoma Highlights"
Feat.
B. D. Cheson
13:07
Moffitt Cancer Center
R/R DLBCL: Are Bispecific Antibodies Superior to CAR-T?
Feat.
J. Chavez
22:09
Scripps Health
New Updates in Frontline DLBCL
Feat.
L. Nastoupil
27:47
Indy Hematology Review
Current Advances in the Treatment of Aggressive B- and T-Cell Lympho…
Feat.
S. Smith
35:27
Louisville Hematology Highlights
Updates on Management of DLBCL
Feat.
J. Leonard
10:04
Tara Graff
How to Incorporate Bispecific Antibodies Into Your NHL Practice: A P…
09:18
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "Primary OS Analysis of the Phase 3 Random…
Feat.
J. Westin
04:04
Wojciech Jurczak
Polatuzumab Vedotin for 1L DLBCL: Results From the POLARIX Trial
08:23
Total Health
R/R DLBCL Case Discussion: 81 y/o Male Needing 3rd Line Treatment
Feat.
J. Chandler,
B. Randolph,
M. Onciu
22:11
SOHO Brazil 2024
Has the 1L SoC Truly Changed in Advanced Stage DLBCL?
Feat.
A. Zelenetz
17:07
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Summary: "Comparative Review of Toxicities and Their…
Feat.
M. Minnema
08:01
Georg Lenz
Treatment Landscape in 1L DLBCL: Polatuzumab Vedotin as SoC
34:36
MyCancerHaven
Frontline DLBCL Treatment Approaches
Feat.
R. Vij,
H. Cherng
15:26
Moffitt Cancer Center
R/R DLBCL: Are CAR-Ts Superior to Bispecific Antibodies?
Feat.
A. Lazaryan
62:02
UChicago Medicine
New Treatment Strategies in DLBCL
Feat.
L. Sehn
13:26
Steven Pavletic
Chronic GvHD: Main Complications After ASCT
29:26
Massachusetts General Hospital Cancer Center
Practice-Changing Updates in DLBCL and HL
Feat.
J. Erika Haydu
16:03
SOHO 2023 Eleventh Annual Meeting
SOHO 2023: The New Algorithm for 2L LBCL
Feat.
J. Westin
04:29
Juan Pablo Alderuccio
Polatuzumab Vedotin in 1L DLBCL: Perspectives on the POLARIX Trial
